

### **REMARKS/ARGUMENTS**

**Claim status.** Claims 2 to 13, 25 and 26 remain pending in this application. Claims 10 and 26 are amended. No claims are added or canceled hereby.

**Amendments to the claims.** The amendment to Claim 10 merely removes the appearance of claiming sequences that have been eliminated from the Sequence Listing. The amendment to Claim 26 eliminates the sequence identification numbers from the formulae, which are not required for the reasons discussed below.

**Amendments to the specification.** The Examiner objected that the amendments to the Sequence Listing were confusing. As a service to the Examiner, the table below shows the concordance between each sequence and the specification.

<b>SEQ ID NO:</b>	<b>CROSS-REFERENCE TO SPECIFICATION</b>
1	Figure 3 (page 10, line 20)
2	Figure 3 (page 10, line 20)
3	Page 26, line 5
4	Page 26, line 6
5	Page 26, line 7
6	Page 26, line 8
7	Page 17, lines 7-8
8	Page 17, lines 10-11
9	Page 17, lines 13-14
10	[eliminated; corresponding amendment to specification filed July 2003]
11	Page 17, lines 17-18
12	[eliminated; corresponding amendment to specification filed January 2005]
13	Page 17, lines 21-22
14	Page 17, lines 23-24
15	Page 17, lines 25-26

16	Page 17, lines 27-28
17	Page 18, lines 3-4
18	Page 18, lines 5-6
19	Page 18, lines 7-8
20	Page 18, lines 9-10
21	Page 18, lines 11-12
22-64	Page 19, Table 3
65-87	Page 20, Table 4
88-94	Page 20, Table 5
95	Page 21, Table 6
96	Page 21, Table 6
97	Page 43, lines 24-25
98	Page 43, lines 26-27
99	Page 43, lines 28-29
100	Page 43, lines 30-31
101	Page 44, line 3
102	Page 44, line 4
103	Page 44, line 5
104	Page 44, lines 9-10
105	Page 44, lines 11-12
106	Page 44, line 17
107	Page 44, lines 18-19
108	Page 45, line 5 to page 46, line 42
109	Page 45, line 5 to page 46, line 42
110	Page 48, lines 1-11
111	Page 48, lines 112-116
112	Page 49, line 6 to page 50, line 32
113	Page 51, lines 5-17
114	Page 51, line 28 to page 52, line 7
115	Page 55, line 10


116	Page 55, line 11
117	Page 55, line 12
118	Page 55, line 13
119	Page 55, line 14
120	Page 55, line 15
121	Page 55, lines 23-24
122	Page 55, lines 26-28
123	Page 55, lines 30-34
124	Page 56, lines 2-4
125	Page 56, lines 6-8
126	Page 56, lines 10-13
127	Page 56, line 14
128-135	Page 21, Table 6
136	Page 57, line 16
137	Page 57, line 17
138-161	Page 17, lines 25-31

The sequence numbers 95 and 96 were originally given to formulae that incorporated linkers of variable length and sequence. The Applicants since determined that such formulae could not be expressed as sequences within the Sequence Listing rules and, further, that inclusion in the Sequence Listing was not required. Note that RGD is too short to fall within the Sequence Listing rules and that the laminin sequence (YIGSR) is SEQ ID NO: 7.

The formulae at page 17, lines 25 and 27 incorporate X-numbered substituents that refer to a defined range of amino acids. The Sequence Listing rules, however, require that each Xaa refer to only one amino acid. Thus, the only way to comply with the Sequence Listing rules is to provide a separate sequence for each permutation within the formulae. The Applicants apologize for failing to include this explanation with the Sequence Listing provided in January 2005. If the Examiner concludes that the permutations within the formulae should not be expressed as sequences within the Sequence Listing, then the Applicants request that the Examiner so state on the record.

**Conclusion.** In view of the foregoing amendments and remarks, the Applicants respectfully request reconsideration of the restriction requirement, entry of all amendments, and allowance of all claims.

Respectfully submitted,



Timothy J. Gaul  
Attorney for Applicant  
Registration No.: 33,111  
Phone: (805) 447-2688  
Date: May 20, 2005

Please send all future correspondence to:  
US Patent Operations/ TJG  
Dept. 430, M/S 27-4-A  
AMGEN INC.  
One Amgen Center Drive  
Thousand Oaks, California 91320-1799